8-K - Cyclerion Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Cyclerion Therapeutics announced a merger with Korsana Biosciences where Korsana stockholders will own ~98.5% of the combined company, supported by $380M PIPE financing, with closing expected Q3 2026 pending approvals.

Key Takeaways

1Merger structure: Reverse triangular merger; pre-merger Cyclerion shareholders to own 1.5%, Korsana 98.5% pro forma pre-financing.

2Concurrent $380M PIPE: Institutional investors purchasing Korsana common stock and pre-funded warrants immediately prior to merger effective time.

3Post-merger leadership: Korsana's CEO Jonathan Violin to lead; Korsana board to form combined company board of 6 members.

4Closing conditions: Shareholder approvals, Nasdaq listing approval, S-4 effectiveness, HSR clearance, $150M minimum PIPE proceeds.

5CVRs for Cyclerion shareholders: Entitled to net proceeds from legacy asset dispositions over 2-15 years.

6Series B Preferred Stock: Convertible 1:1000 to common; grants Korsana control rights while 30%+ outstanding.

Current Report Details

Event Type

Management Change+4 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

of this Current Report on Form 8-K is incorporated herein by reference. On April 1, 2026, the Company entered into an amended and restated offer letter (the “ A

Material Agreement

$150.0K

Source Document

5.01

Changes in Control of Registrant. To the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated

Corporate Governance

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. To the extent

Management Change

7.01

, including Exhibits 99.1 , 99.2 and 99.3 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as ame

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number: 2.1* | Description: Agreement and Plan of Merger and Reorganization, dated as of April 1, 2026,

Exhibits Only

Source Document

Executive & Director Changes

Jonathan Violin, Ph.D.

President and Chief Executive Officer

Appointed to lead combined company

Effective: Closing

Korsana's current CEO

Regina Graul, Ph.D.

President and Chief Executive Officer

Amended offer letter with transaction bonus up to $150K and severance

Effective: April 1, 2026

In connection with merger

Transaction Details

Acquisition / Disposition

Target: Korsana Biosciences, Inc. (100% equity)
Consideration: All-stock; Korsana stockholders ~98.5% ownership post-merger pre-PIPE (pro forma).
Structure: Reverse triangular merger via wholly-owned merger subs.

•Expected Q3 2026
•Cyclerion/ Korsana shareholder approval
•Nasdaq listing approval
•S-4 effectiveness
•HSR waiting period expiration
•$150M minimum PIPE proceeds

Material Agreement

Agreement: Agreement and Plan of Merger and Reorganization
Parties: Cyclerion Therapeutics, Inc., Cariboos Merger Sub Corp., Cariboos Merger Sub II, LLC, Korsana Biosciences, Inc.

•Two-step merger: First Merger Sub merges into Korsana (Korsana survives as Cyclerion subsidiary), followed by Korsana merger into Second Merger Sub.
•Exchange ratio based on $268.4M Korsana equity value + PIPE proceeds vs. Cyclerion $10M valuation adjusted for net cash.
•Closing expected Q3 2026 subject to shareholder approvals, Nasdaq listing, S-4 effectiveness, HSR clearance.
•PIPE: ~$380M securities purchase agreement for Korsana common stock/pre-funded warrants prior to effective time.
•CVR Agreement: Cyclerion pre-merger shareholders receive CVRs for legacy asset disposition net proceeds over 2-15 years.

Exhibits (13)

10.1

EX-10.1

10.2

EX-10.2

10.3

EX-10.3

10.4

EX-10.4

10.5

EX-10.5

10.6

EX-10.6

10.7

EX-10.7

2.1

EX-2.1

3.1

EX-3.1

8-K

99.1

EX-99.1

99.2

EX-99.2

99.3

EX-99.3